Table 1.

Clinical information and demographics of the patients included in the study (n = 82)

Female82 (100%)
Median age52 y (range 29-79)
Race
    Caucasian56 (68%)
    African American11 (13%)
    Asian7 (9%)
    Hispanic6 (7%)
    Mixed2 (2%)
Histology
    Invasive ductal73 (89%)
    Mixed ductal/lobular6 (7%)
    Invasive lobular1 (1%)
    Invasive mucinous2 (2%)
Tumor-node-metastasis stage
    T17 (9%)
    T246 (56%)
    T315 (18%)
    T414 (17%)
    N028 (34%)
    N138 (46%)
    N28 (10%)
    N38 (10%)
Nuclear grade (benign melanocytic nevus)
    12 (2%)
    223 (37%)
    335 (61%)
Estrogen receptor positive*35 (43%)
Estrogen receptor negative47 (57%)
HER-2 positive57 (70%)
HER-2 negative25 (30%)
Neoadjuvant therapy
    Weekly T (80 mg/m2) × 12 + FAC × 469 (84%)
    3-weekly T (225 mg/m CI) × 4 + FAC × 413 (16%)
Pathologic CR21 (26%)
Residuald isease61 (74%)
  • * Cases where >10% of tumor cells stained positive for estrogen receptor with immunohistochemistry were considered positive.

  • Cases that showed gene copy number >2.0 were considered HER-2 positive.

  • T, paclitaxel; CI, 24-hour continuous infusion; and FAC, 5-flurouracil (500 mg/m2), doxorubicin (50 mg/m2), and cyclophosphamide (500 mg/m2).